Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 6/20 | 0.59 |
| ▸ | KDR | P35968 | 4/20 | 0.53 |
| ▸ | TEK | Q02763 | 4/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | UBE2N | P61088 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1784928 | 0.99 | AURKA (0.59) | AURKAKDRTEKCHEK1CDK1 | |
| SCHEMBL1786913 | 0.98 | AURKA (0.59) | AURKAKDRTEKCHEK1CDK1 | |
| SCHEMBL1786452 | 0.93 | AURKA (0.59) | AURKAKDRTEKCHEK1CDK1 | |
| SCHEMBL1786914 | 0.92 | AURKA (0.57) | AURKAKDRTEKCHEK1CDK1 | |
| SCHEMBL14467225 | 0.91 | AURKA (0.56) | AURKAKDRTEKCHEK1CDK1 | |
| SCHEMBL1787383 | 0.91 | AURKA (0.59) | AURKAKDRTEKCHEK1CDK1 | |
| SCHEMBL1786309 | 0.88 | AURKA (0.58) | AURKAKDRTEKCHEK1CDK1 | |
| SCHEMBL1785548 | 0.87 | AURKA (0.56) | AURKAKDRTEKCHEK1CDK1 | |
| SCHEMBL1785776 | 0.86 | AURKA (0.56) | AURKAKDRTEKCHEK1CDK1 | |
| SCHEMBL1786150 | 0.86 | AURKA (0.57) | AURKAKDRTEKCHEK1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324222-B2 | Cyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-04 | — | — | US | disclosed |
| US-20110124665-A1 | Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124665-A1 | Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof | DPYD, TK2, TPMT | AURKA 3192/4885KDR 511/4885TEK 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.